1. The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis. (4th May 2019) Authors: Freedman, M. S.; Duquette, P.; Grand'Maison, F.; Lee, L.; Vorobeychik, G.; Lara, N.; Khurana, V.; Nakhaipour, H. R.; Schecter, R.; Haddad, P. Journal: Current medical research and opinion Issue: Volume 35:Number 5(2019) Page Start: 767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon‐β therapy. (15th November 2013) Authors: Freedman, M. S. Journal: European journal of neurology Issue: Volume 21:Number 3(2014:Mar.) Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗